Clinical management of premalignant disorders of the gastrointestinal tractWADLER, Scott; KATZ, Julian; REYNOLDS, James C et al.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, issn 0889-8588, 338 p.Serial Issue

SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cellsBO YU; LANE, Maureen E; WADLER, Scott et al.Biochemical pharmacology. 2002, Vol 64, Num 7, pp 1091-1100, issn 0006-2952, 10 p.Article

Interferon-mediated fatigueMALIK, Ummekalsoom R; MAKOWER, Della F; WADLER, Scott et al.Cancer. 2001, Vol 92, Num 6, pp 1664-1668, issn 0008-543X, SUPConference Paper

Histologic precursors of gastrointestinal tract malignancyHABER, Marian M.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, issn 0889-8588, viii, 389-412 [24 p.]Article

Barrett's esophagus: Surveillance and treatmentKATZKA, David A.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, pp ix-x, issn 0889-8588, 18 p.Article

Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumorsKAUBISCH, Andreas; KALEYA, Ron; HAYNES, Hilda et al.Cancer chemotherapy and pharmacology. 2004, Vol 53, Num 4, pp 337-340, issn 0344-5704, 4 p.Article

Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusionWADLER, Scott; MAKOWER, Della; CLAIRMONT, Caroline et al.Journal of clinical oncology. 2004, Vol 22, Num 9, pp 1553-1563, issn 0732-183X, 11 p.Article

The early diagnosis and prevention of gastrointestinal cancer: Problems and promisesKATZ, Julian; REYNOLDS, James C.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, issn 0889-8588, vii, 351-360 [10 p.]Article

The epidemic of esophageal adenocarcinomaEL-SERAG, Hashem B.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, issn 0889-8588, viii, 413-432 [20 p.]Article

Role of Helicobacter pylori in gastric carcinogenesisSEPULVEDA, Antonia R; GRAHAM, David Y.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, issn 0889-8588, x, 505-523 [19 p.]Article

Cellular and molecular mechanisms of carcinogenesisKATZ, Jonathan P; KAESTNER, Klaus H.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, issn 0889-8588, vii, 361-376 [17 p.]Article

Colorectal cancer in inflammatory bowel disease: Molecular and clinical featuresMURTHY, Sreekant; FLANIGAN, Anne; CLEARFIELD, Harris et al.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, pp x-xi, issn 0889-8588, 14 p.Article

Diagnosis and management of hereditary colon cancerCRUZ-CORREA, Marcia; GIARDIELLO, Francis M.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, issn 0889-8588, xi, 539-551 [13 p.]Article

c-myc/p53 Interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivoARANGO, Diego; CORNER, Georgia A; WADLER, Scott et al.Cancer research (Baltimore). 2001, Vol 61, Num 12, pp 4910-4915, issn 0008-5472Article

Multifocal atrophic gastritis and gastric carcinomaFARAJI, E. Isaac; FRANK, Barbara B.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, issn 0889-8588, x, 487-504 [18 p.]Article

Cellular and molecular mechanisms responsible for progression of Barrett's metaplasia to esophageal carcinomaBEILSTEIN, Michelle; SILBERG, Debra.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, issn 0889-8588, ix, 453-470 [18 p.]Article

Hepatocellular carcinoma: Predisposing conditions and precursor lesionsBAILEY, Marie Ann; BRUNT, Elizabeth M.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, issn 0889-8588, xii, 625-646 [12 p.]Article

Pancreatitis as a risk for pancreatic cancerWHITCOMB, David C; POGUE-GEILE, Katherine.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, pp xii-xiii, issn 0889-8588, 16 p.Article

Decreased short- and long-term Swallowing problems with altered radiotherapy dosing used in an organ-sparing protocol for advanced pharyngeal carcinomaSMITH, Richard V; GOLDMAN, S. Yedida; BEITLER, Jonathan J et al.Archives of otolaryngology, head & neck surgery. 2004, Vol 130, Num 7, pp 831-836, issn 0886-4470, 6 p.Article

Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-α-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: Eastern Cooperative Oncology Group Study E6296WADLER, Scott; BRAIN, Carlos; CATALANO, Paul et al.The Cancer journal (Sudbury, Mass. Print). 2002, Vol 8, Num 3, pp 282-286, issn 1528-9117Article

Barrett's esophagus: Clinical characteristicsREYNOLDS, James C; RAHIMI, Poneh; HIRSCHL, David et al.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, issn 0889-8588, ix, 433-451 [19 p.]Article

Primary prevention of colorectal cancer: Diet and drugsGATOF, David; AHNEN, Dennis.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, pp xi-xii, issn 0889-8588, 37 p.Article

Celiac disease and other precursors to small-bowel malignancyGREEN, Peter H. R; JABRI, Bana.Hematology/oncology clinics of North America. 2003, Vol 17, Num 2, issn 0889-8588, xii, 611-624 [14 p.]Article

Mortality associated with irinotecan plus bolus fluorouracil/leucovorin : summary findings of an independent panelROTHENBERG, Mace L; MEROPOL, Neal J; POPLIN, Elizabeth A et al.Journal of clinical oncology. 2001, Vol 19, Num 18, pp 3801-3807, issn 0732-183XArticle

Recommended guidelines for the treatment of cancer treatment-induced diarrheaBENSON, Al B; AJANI, Jaffer A; WADLER, Scott et al.Journal of clinical oncology. 2004, Vol 22, Num 14, pp 2918-2926, issn 0732-183X, 9 p.Article